BRIEF published on 03/18/2024 at 15:32, 8 months 2 days ago The Vanguard Group, Inc. Announces Increased Stake in Ageas SA/NV The Vanguard Group Financial Disclosure Stock Transactions Ageas SA/NV Insurance Sector
PRESS RELEASE published on 03/18/2024 at 15:27, 8 months 2 days ago Form 8.3 - The Vanguard Group, Inc.: Ageas SA/NV The Vanguard Group, Inc. discloses a 3.46% stake in Ageas SA/NV as of 15 March 2024 per Form 8.3. Additional disclosure for Direct Line Insurance Group plc Form 8.3 Disclosure The Vanguard Group Ageas SA/NV Direct Line Insurance Group Plc
BRIEF published on 03/15/2024 at 14:51, 8 months 5 days ago Vanguard Group Discloses Stake in Ageas SA/NV Takeover Code Vanguard Group Financial Disclosure Securities Ownership Ageas SA/NV
PRESS RELEASE published on 03/15/2024 at 14:46, 8 months 5 days ago Form 8.3 - The Vanguard Group, Inc.: Ageas SA/NV The Vanguard Group, Inc. discloses a position of 3.46% in Ageas SA/NV. Details on ownership and dealing disclosed in Form 8.3 under Takeover Code Rule 8.3 The Vanguard Group, Inc. Form 8.3 Takeover Code Ownership Disclosure Ageas SA/NV
BRIEF published on 03/14/2024 at 14:24, 8 months 7 days ago The Vanguard Group, Inc. Discloses Stake in Ageas SA/NV The Vanguard Group Stake Disclosure Ageas SA/NV Investment Activities Insurance Sector
PRESS RELEASE published on 03/14/2024 at 14:19, 8 months 7 days ago Form 8.3 - The Vanguard Group, Inc.: Ageas SA/NV The Vanguard Group, Inc. discloses a 3.44% interest in Ageas SA/NV. Deals in ordinary securities were made at 39.53 EUR and 39.76 EUR per unit The Vanguard Group, Inc. Disclosure Ageas SA/NV Ordinary Securities Deals
BRIEF published on 03/13/2024 at 13:47, 8 months 8 days ago Vanguard Group Announces Stake in Ageas SA/NV Stock Purchase Vanguard Group Ageas SA/NV Insurance Sector Investment Holding
PRESS RELEASE published on 03/13/2024 at 13:42, 8 months 8 days ago Form 8.3 - The Vanguard Group, Inc.: Ageas SA/NV The Vanguard Group, Inc. discloses a 3.44% stake in Ageas SA/NV. Dealings include purchase of 1,440 securities at 39.61 EUR per unit Securities Dealings The Vanguard Group Inc. Financial Disclosure Stake Disclosure Ageas SA/NV
BRIEF published on 03/12/2024 at 14:23, 8 months 9 days ago Vanguard Group Discloses Stake in Ageas SA/NV Vanguard Group Financial Disclosure Shareholding Regulatory Filing Ageas SA/NV
PRESS RELEASE published on 03/12/2024 at 14:18, 8 months 9 days ago Form 8.3 - The Vanguard Group, Inc.: Ageas SA/NV The Vanguard Group, Inc. discloses 3.44% ownership in Ageas SA/NV. Details on the Form 8.3 filing revealed on 12-March-2024 The Vanguard Group, Inc. Form 8.3 Ownership Disclosure Financial Securities Ageas SA/NV
Published on 11/21/2024 at 14:15, 11 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 26 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 26 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 26 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 10 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 11 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 51 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 28 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 6 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 41 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 41 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
